Skip to main content
. 2022 Aug 31;28(21):4642–4648. doi: 10.1158/1078-0432.CCR-22-1528

Table 3.

Summary of AEs (safety analysis set).

Atezolizumab + bevacizumab
N = 43
Any AE 41 (95.3)
Grade ≥3 AE 11 (25.6)
AE leading to treatment interruption 7 (16.3)
AE leading to treatment discontinuation 2 (4.7)
AE leading to death 1 (2.3)
Atezolizumab-related AE 39 (90.7)
Atezolizumab-related serious AE 7 (16.3)
Bevacizumab-related AE 38 (88.4)
Bevacizumab-related serious AE 7 (16.3)

Note: Data are n (%).